CNS Pharmaceuticals Inc (CNSP) Stock: What Does the Chart Say Friday?

Overall market sentiment has been down on CNS Pharmaceuticals Inc (CNSP) stock lately. CNSP receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

CNS Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CNSP!

See Full CNSP Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CNSP Stock Today?

CNS Pharmaceuticals Inc (CNSP) stock is trading at $2.18 as of 10:16 AM on Friday, Oct 27, an increase of $0.20, or 10.13% from the previous closing price of $1.98. The stock has traded between $2.00 and $2.22 so far today. Volume today is less active than usual. So far 14,398 shares have traded compared to average volume of 82,635 shares.

More About CNS Pharmaceuticals Inc

CNS Pharmaceuticals Inc is a preclinical stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Click Here to get the full Stock Report for CNS Pharmaceuticals Inc stock.